Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors

Simple Summary Treatment options for advanced thymic malignancies are limited. Immune checkpoint inhibitors are effective against advanced thymic epithelial tumors, but the treatment is associated with an elevated risk for adverse events. In this article, we aim to highlight new insights regarding predictive markers for treatment efficacy and risk of adverse events that would allow for safe and precise clinical indications for immunotherapy in thymic malignancies. Thymic epithelial tumors (TETs) are rare thoracic malignancies with a favorable prognosis when complete surgical resection can be achieved. Therapeutic options for advanced, irresectable, or recurrent disease are limited and currently, a therapeutic standard treatment beyond platinum-based chemotherapy is undefined. Immune checkpoint inhibitors are effective against TETs, however their use is associated with a serious risk of immune-mediated toxicity. In this article, we highlight new insights regarding markers of predictive value for both treatment efficacy and risk of adverse effects in immune checkpoint inhibitor treatment for thymic epithelial tumors.

Automated summary

Treatment options for advanced thymic malignancies are limited. Immune checkpoint inhibitors are effective against thymic epithelial tumors, but carry a high risk of adverse events. This article aims to provide new insights on predictive markers for treatment efficacy and risk of adverse events, allowing for safe and precise clinical indications for immunotherapy in thymic malignancies.